Our guys (and gal) are good - but you knew that! Sometimes their picks are truly quicker than the ticker. Find out which ones really paid off.
What’s the biggest event of the year for biotech and big pharma? It’s the 43rd ASCO Annual Meeting where drug companies present new research that could indicate whether their cancer drugs are blockbusters or duds. It starts this Friday night in Chicago - what should you expect?
Good morning all. We're starting this last day on the rough side as more than half of our Million Dollar contestants lost ground Thursday in a volatile market. All of our finalists are fully invested, with the exception of #15, Chuck Chow who is all in cash. Nancy Beaumont holds first place for the 4th straight day on the 9% gain of Gymboree. Nancy may hold onto the top spot with her almost all-in trade on Verigy, a Singapore-based maker of test systems for the semiconductor industry, which beat estimates after the bell Thursday. Verigy was up almost 10% in extended hours.
Good morning everyone. Today--Thursday--is a big day for our contestants. The trades they execute prior to 4pm will be the last trades that will impact their total portfolio value based on their performance on Friday. And, the race at the top gets tighter each day. Only $22K separates the top three positions. Nancy Beaumont holds first place for the 3rd straight day on the 9.75% gain of The Men's Wearhouse. Nancy looks like she may maintain her first position with Gymboree up almost 10% in extended hours.
Even with a bull market raging on, corporate America is still making like Ebenezer Scrooge when it comes to sharing the wealth with shareholders. Exxon Mobil (XOM), Microsoft (MSFT), Pfizer (PFE) and Cisco (CSCO) are all sitting on more than $20 billion, individually. Shareholders need to start demanding they put this money to work or return it. So which stocks should you buy in anticipation of that?
Stocks prices are edging higher this morning, following the direction of European markets. Lots of earnings news is out today, and talk of deals in the media industry swirl.
Genentech and Biogen Idec said their blockbuster Rituxan drug for lymph cancer was highly effective against multiple sclerosis in a small mid-stage trial.
In a previous blog post, I wrote about what happened at this year's American College of Cardiology conference in New Orleans when at least one doctor "leaked" the results of a major, highly anticipated study comparing drug-coated stents to old-fashioned heart drugs. The ACC had to move up the embargo time of the data by one day and reporters had to scramble to meet the hastened deadline.
Elan reported a smaller fourth-quarter loss and higher sales Tuesday, citing the expansion of its multiple sclerosis-fighting drug Tysabri as a major factor.
While on Capitol Hill the new Congress begins to take on the pharmaceuticals industry, the healthcare investment community is holding its annual confab in the hills of San Francisco--House Speaker Nancy Pelosi's home district. I'm at the 25th Annual JPMorgan Healthcare Conference at the Westin St. Francis on Union Square. The four-day event is just getting started, but the halls are...
Financial markets will have plenty of news to feast on in the coming week although the markets generated enough headlines on their own in the first days of January with just a few big stories to chew on. The second week of January is quite busy. We're looking forward to some of the most important and newsy industry conferences of the year, plus the start of earnings season, an important Fed speech, and some fresh economic data.
Stocks closed mostly higher as investors shrugged off the latest inflation news and energy shares rallied on strength in crude prices.
The same rare, but fatal viral infection that forced Biogen Idec and Elan to recall, and recently relaunch, the multiple sclerosis drug, Tysabri, may also be a side effect of Rituxan, also from Biogen Idec and Genentech. In an SEC filing -- not a press release -- and on the FDA website, the companies and the agency disclosed yesterday evening that two people with lupus died after taking Rituxan.
Two lupus patients died from a rare brain infection after taking the Genentech and Biogen drug Rituxan, U.S. health officials said in an advisory issued Monday.
The deaths of two people from a rare brain infection has prompted the U.S. Food and Drug Administration to issue a warning on the drug Rituxan. CNBC's Mike Huckman was on "Squawk Box" with the details. Huckman said the deaths were caused by a rare brain infection (called PML) to patients with lupus--who were taking the drug to combat their disease.